| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/1440-1681.12026 |
| P953 | full work available at URL | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2F1440-1681.12026 |
| https://onlinelibrary.wiley.com/doi/pdf/10.1111/1440-1681.12026 | ||
| P698 | PubMed publication ID | 23110505 |
| P2093 | author name string | Yan Zou | |
| Tao Jiang | |||
| Wen-Jing Xing | |||
| Huan Ren | |||
| Xiao-Hong Lv | |||
| Qing-Lian Han | |||
| Yu-Cui Dong | |||
| Zhen-Ling Deng | |||
| P2860 | cites work | Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells | Q24550891 |
| Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma | Q24632791 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 | ||
| Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain | Q27865182 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy | Q30437740 | ||
| Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. | Q33407127 | ||
| Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance | Q34105339 | ||
| mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo | Q34542438 | ||
| MAPK pathways in radiation responses | Q35208830 | ||
| Elevated PI3K signaling drives multiple Breast Cancer subtypes | Q35640263 | ||
| Therapeutic targeting of receptor tyrosine kinases in lung cancer | Q36158717 | ||
| A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma | Q37003323 | ||
| Receptor tyrosine kinases as therapeutic targets in malignant glioma. | Q37161247 | ||
| The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts | Q37302262 | ||
| EGFR signals to mTOR through PKC and independently of Akt in glioma | Q37476332 | ||
| Molecular Heterogeneity in Glioblastoma: Therapeutic Opportunities and Challenges | Q37855231 | ||
| Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells | Q39308739 | ||
| The functional expression of calcium-sensing receptors in BRL cells and related signal transduction pathway responsible for intracellular calcium elevation | Q39701651 | ||
| Suppression of invasive properties of colorectal carcinoma SW480 cells by 15-hydroxyprostaglandin dehydrogenase gene | Q39912197 | ||
| Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells | Q40243368 | ||
| Effects of cotransfection of antisense-EGFR and wild-type PTEN cDNA on human glioblastoma cells | Q40268565 | ||
| Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib | Q43742602 | ||
| Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. | Q46410598 | ||
| Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis | Q46448054 | ||
| Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? | Q46547355 | ||
| Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. | Q48445523 | ||
| Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas | Q48475005 | ||
| Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient's age but not with tumor's clinicopathological pathway | Q48776725 | ||
| PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. | Q55474170 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 13-21 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Clinical and Experimental Pharmacology and Physiology | Q5133807 |
| P1476 | title | Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors | |
| P478 | volume | 40 |
| Q35804765 | Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells |
| Q37362563 | Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes. |
| Q55456636 | Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. |
| Q33746514 | Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science |
| Q39136061 | Is Mda‐7/IL‐24 a Potential Target and Biomarker for Enhancing Drug Sensitivity in Human Glioma U87 Cell Line? |
| Q34062038 | JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma |
| Q38102636 | Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding |
| Q38987085 | mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells |
Search more.